

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

COSMO TECHNOLOGIES LIMITED,
Patent Owner.

U.S. Patent No. 9,320,716 to Villa *et al.*
Case No.: IPR2017-01035

U.S. Patent No. 8,784,888 to Villa *et al.*
Case No.: IPR2017-01034

DECLARATION OF ANTHONY PALMIERI III, PH.D, R.PH.

Table of Contents

I.	INTRODUCTION	1
II.	MY EXPERIENCE AND QUALIFICATIONS	2
III.	LIST OF MATERIALS CONSIDERED.....	6
IV.	LEGAL STANDARD.....	9
	A. Anticipation	10
	B. Obviousness.....	11
V.	PERSON OF ORDINARY SKILL IN THE ART (“POSA”).....	13
VI.	THE VILLA PATENTS	14
VII.	CLAIM CONSTRUCTION	17
VIII.	SCOPE AND CONTENT OF THE PRIOR ART	19
	A. Controlled Release Oral Compositions	20
	B. Budesonide	24
IX.	INVALIDITY OF THE ’716 PATENT	24
	A. The ’584 Patent Anticipates Claims 1-29 of the ’716 Patent	24
	1. Independent Claims	24
	a) “at least one lipophilic compound”	30
	b) “at least one hydrophilic compound”	31
	c) “at least one amphiphilic compound”	31
	d) “macroscopically homogenous structure controls the release of the budesonide”	32
	2. Dependent Claims.....	34
	B. The ’584 Patent Renders Obvious Claims 1-29 of the ’716 Patent	38
	1. Claim 1	39
	a) “A controlled release oral pharmaceutical composition comprising: (i) budesonide in an amount effective to treat intestinal inflammatory disease”.....	39
	b) “a macroscopically homogenous structure comprising”	40
	c) “at least one lipophilic compound”	42

Declaration of Anthony Palmieri III, Ph.D, R.Ph.

d)	“at least one hydrophilic compound”	44
e)	“wherein the macroscopically homogenous structure controls the release of the budesonide”	45
f)	“a gastro-resistant coating on the macroscopically homogenous structure that prevents release of budesonide in the stomach”	45
g)	“wherein the macroscopically homogenous structure is a tablet”	46
2.	Claims 6, 12, and 22: “at least one amphiphilic compound”	46
3.	Claims 2 and 13: “wherein the gastro-resistant coating is . . . methacrylic acid polymers and cellulose derivatives”	48
4.	Claims 3-5 and 14-16: “wherein the at least one hydrophilic compound is . . . a hydroxyalkyl cellulose”	49
5.	Claims 7, 8, 17 and 18: “wherein the at least one amphiphilic compound . . . lecithin”	50
6.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is selected from the group consisting of an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof . . .”/“lipophilic compound is stearic acid”	50
7.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising . . . an acrylic acid polymer”	52
8.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	53
9.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”	53
10.	Reasonable Expectation of Success.....	54
C.	The ’388 Patent Anticipates Claims 1-7, 9, 11-17, 19, and 21-29 of the ’716 Patent.....	54
1.	Independent Claims	54
2.	Dependent Claims.....	63
D.	The ’388 Patent Renders Obvious Claims 1-29 of the ’716 Patent	66
1.	Claim 1	66

Declaration of Anthony Palmieri III, Ph.D, R.Ph.

a)	“A controlled release oral pharmaceutical composition comprising: (i) budesonide in an amount effective to treat intestinal inflammatory disease”.....	66
b)	“a macroscopically homogenous structure comprising”	68
c)	“at least one lipophilic compound”	68
d)	“at least one hydrophilic compound”	69
e)	“wherein the macroscopically homogenous structure controls the release of the budesonide”.....	69
f)	“a gastro-resistant coating on the macroscopically homogenous structure that prevents release of budesonide in the stomach”	69
g)	“wherein the macroscopically homogenous structure is a tablet”	70
2.	Claims 6, 12, and 22: “at least one amphiphilic compound”	70
3.	Claims 2 and 13: “wherein the gastro-resistant coating is . . . methacrylic acid polymers and cellulose derivatives”	71
4.	Claims 3-5 and 14-16: “wherein the at least one hydrophilic compound is . . . a hydroxyalkyl cellulose”	72
5.	Claims 7, 8, 17 and 18: “wherein the at least one amphiphilic compound is [phosphatidylcholines/lecithin]”	72
6.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is selected from the group consisting of an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof . . .”/“lipophilic compound is stearic acid”	74
7.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising . . . an acrylic acid polymer”	75
8.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	76
9.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”	76
10.	Reasonable Expectation of Success.....	77

Declaration of Anthony Palmieri III, Ph.D, R.Ph.

E.	The '388 Patent in View of the '584 Patent Renders Obvious Claims 8, 10, 18, and 20 of the '716 Patent.....	77
1.	Claims 8 and 18: wherein the at least one amphiphilic compound is lecithin”	77
2.	Claims 10 and 20: “wherein the at least one lipophilic compound is stearic acid”	79
X.	INVALIDITY OF THE '888 PATENT	80
A.	The '120 Patent and '584 Patent Renders Obvious Claims 1-9 of the '888 Patent.....	80
1.	Claim 1	81
a)	“A controlled release oral pharmaceutical composition consisting essentially of”	81
b)	“a tablet core consisting essentially of”	81
c)	“budesonide in an amount effective to treat intestinal inflammatory disease”	81
d)	“a macroscopically homogeneous composition comprising”	82
(1)	“at least one lipophilic excipient”	84
(2)	“at least one amphiphilic excipient”	84
(3)	“at least one hydrogel-forming hydrophilic excipient other than a gum”	85
e)	“wherein said budesonide is dispersed in said macroscopically homogeneous composition”.....	86
f)	“a coating on said tablet core, said coating consisting essentially of a gastro-resistant film”	87
g)	Reasonable Expectation of Success.....	87
2.	Claims 2, 4, 6, 8: “at least one hydrogel-forming hydrophilic excipient comprises at least one hydroxyalkyl cellulose”	88
3.	Claim 3: “said gastro-resistant film consists essentially of at least one methacrylic acid polymer”	88
4.	Claims 5 and 9: “at least one lipophilic excipient comprises stearic acid or magnesium stearate”	89
5.	Claim 7: “at least one amphiphilic excipient comprises lecithin”	89
B.	The '584 Patent Renders Obvious Claims 1-9 of the '888 Patent	90
1.	Claim 1	90
a)	“A controlled release oral pharmaceutical composition”.....	90

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.